Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
Authors:
- Tianqi XuTXTianqi Xu
- Anzhelika VorobyevaAVAnzhelika Vorobyeva
- Alexey SchulgaASAlexey Schulga
- Elena KonovalovaEKElena Konovalova
- Olga VorontsovaOVOlga Vorontsova
- Haozhong DingHDHaozhong Ding
- Torbjörn GräslundTGTorbjörn Gräslund
- Liubov A. TashirevaLTLiubov A. Tashireva
- Anna OrlovaAnna Orlova
- Vladimir TolmachevVladimir Tolmachev
- Sergey M. DeyevSDSergey M. Deyev
Open Access
Abstract
Efficient treatment of disseminated ovarian cancer (OC) is challenging due to its heterogeneity and chemoresistance. Overexpression of human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM) in approx. 30% and 70% of ovarian cancers, respectively, allows for co-targeted treatment. The clinical efficacy of the monoclonal antibody trastuzumab in patients with HER2-positive breast, gastric and gastroesophageal cancers makes it readily available as the HER2-targeting component. As the EpCAM-targeting component, we investigated the designed ankyrin repeat protein (DARPin) Ec1 fused to a truncated variant of Pseudomonas exotoxin A with reduced immunogenicity and low general toxicity (LoPE). Ec1-LoPE was radiolabeled, evaluated in ovarian cancer cells in vitro and its biodistribution and tumor-targeting properties were studied in vivo. The therapeutic efficacy of Ec1-LoPE alone and in combination with trastuzumab was studied in mice bearing EpCAM- and HER2-expressing SKOV3 xenografts. SPECT/CT imaging enabled visualization of EpCAM and HER2 expression in the tumors. Co-treatment using Ec1-LoPE and trastuzumab was more effective at reducing tumor growth and prolonged the median survival of mice compared with mice in the control and monotherapy groups. Repeated administration of Ec1-LoPE was well tolerated without signs of hepatic or kidney toxicity. Co-treatment with trastuzumab and Ec1-LoPE might be a potential therapeutic strategy for HER2- and EpCAM-positive OC.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (075-15-2019-1925)
- Cancerfonden (20 0181 P, 20 0893 Pj)
This publication has 88 references indexed in Scilit:
- Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based onPseudomonasexotoxin AProceedings of the National Academy of Sciences, 2012
- Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopesProceedings of the National Academy of Sciences, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancerBritish Journal of Cancer, 2011
- Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeuticsProceedings of the National Academy of Sciences, 2010
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathwayBritish Journal of Cancer, 2007